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Background: A subset of human hepatocellular carcinomas (HCC) exhibit mutations of b-catenin gene CTNNB1 and overexpress
Glutamine synthetase (GS). The CTNNB1-mutated HCC cell line HepG2 is sensitive to glutamine starvation induced in vitro with
the antileukemic drug Crisantaspase and the GS inhibitor methionine-L-sulfoximine (MSO).
Methods: Immunodeficient mice with subcutaneous xenografts of the CTNNB1-mutated HCC cell lines HepG2 and HC-AFW1 were
treated with Crisantaspase and/or MSO, and tumour growth was monitored. At the end of treatment, tumour weight and histology
were assessed. Serum and tissue amino acids were determined by HPLC. Gene and protein expression were estimated with RT-PCR
and western blot and GS activity with a colorimetric method. mTOR activity was evaluated from the phosphorylation of p70S6K1.
Results: Crisantaspase and MSO depleted serum glutamine, lowered glutamine in liver and tumour tissue, and inhibited liver GS
activity. HepG2 tumour growth was significantly reduced by either Crisantaspase or MSO, and completely suppressed by the
combined treatment. The combined treatment was also effective against xenografts of the HC-AFW1 cell line, which is
Crisantaspase resistant in vitro.
Conclusions: The combination of Crisantaspase and MSO reduces glutamine supply to CTNNB1-mutated HCC xenografts and
hinders their growth.
Hepatocellular carcinoma is the third leading cause of cancer death
worldwide (Ferlay et al, 2010; El-Serag 2011). High HCC mortality
(Shariff et al, 2009; Ferlay et al, 2010) derives from several causes,
including underlying chronic liver disease, late diagnosis, poor
resectability, frequent local recurrence, and lack of effective anti-
tumour drugs.
Hepatocellular carcinoma is a genetically heterogeneous and
complex tumour. So far, molecular data have poorly contributed to
explain the clinical variability of the disease and have not resulted
into prognostic and predictive biomarkers (El-Serag 2011). Several
attempts to correlate transcriptome, genotype and phenotype have
been performed (Boyault et al, 2007; Hoshida et al, 2008; Roessler
et al, 2012). In one of these (Boyault et al, 2007), six HCC
subgroups (G1–G6) associated with clinical and genetic character-
istics were identified based on unsupervised transcriptome analysis.
G1 and G2 tumours had AKT activation and were associated with
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low (G1) or high (G2) copy number of HBV and overexpression of
genes expressed in fetal liver (G1) or mutations in PIK3CA and
TP53. G3 tumours were characterised by mutation of TP53, whereas
G4 tumours were an heterogeneous subgroup including TCF1-
mutated cancers. G5 and G6 were both related to mutations of
CTNNB1, the gene that encodes for b-catenin, and (in particular G6)
Wnt pathway activation (Boyault et al, 2007). Tumours with
activating mutations of CTNNB1 reproducibly segregate in different
studies as a group with distinctive clinical and genetic characteristics
(Legoix et al, 1999; Chiang et al, 2008; Cieply et al, 2009).
The frequency of CTNNB1 mutations in human HCC ranges
from 3% to 44% (White et al, 2012), leading to the synthesis of a
transcriptionally active mutant protein that is resistant to
proteasomal degradation and accumulates in the nucleus. These
tumours show constitutive activation of the Wnt canonical
pathway, display distinctive histology (Dal Bello et al, 2010) and
overexpress a number of target genes included in the functional
category of amino-acid metabolism (Boyault et al, 2007), such as
GLUL, which encodes for Glutamine synthetase (GS). Glutamine
synthetase is the only enzyme that is able to synthesise L-glutamine
(Gln) from L-glutamate and ammonium. Mutations in other
upstream components of the Wnt pathway, such as the AXIN1
gene, may have the same functional effect (White et al, 2012).
Interest on amino-acid metabolism in cancer has been recently
fuelled by findings, indicating that some tumours require high Gln
availability and are severely inhibited by Gln depletion (Wise et al,
2008). Intracellular Gln can be pharmacologically depleted by
means of the bacterial enzyme Crisantaspase (L-Asparaginase from
Erwinia chrysanthemi, CRIS) and the GS inhibitor methionine-L-
sulfoximine (MSO) (Rotoli et al, 2005; Tardito et al, 2007).
Previous results from our group indicated that the CTNNB1-
mutated HepG2 cell line was the most sensitive to CRIS and MSO
in a panel of HCC cell lines (Tardito et al, 2011).
In the present study, we tested the effects of pharmacologically
induced Gln depletion in vivo using murine xenografts induced by
two different CTNNB1-mutated HCC cell lines.
MATERIALS AND METHODS
Cell culture. The CTNNB1-mutated HCC cell line HepG2, a gift
by prof Giovanni Raimondo, Laboratory of Molecular Biology and
Hepatology, Department of Internal Medicine, University of
Messina, Italy, was grown in low-glucose (1 g l 1) Dulbecco’s
modified Eagle’s Medium (DMEM, cat n. ECM0749L, Euroclone,
Pero, Italy), supplemented with 10% of fetal bovine serum (FBS,
Lonza, Switzerland), 4mM Gln and antibiotics (100Uml 1
penicillin, and 100 mgml 1 streptomycin).
The CTNNB1-mutated paediatric HCCHC-AFW1 cell line
(Armeanu-Ebinger et al, 2012) was grown in high-glucose
(4.5 g l 1) DMEM supplemented with 10% FBS, 2mM Gln and
antibiotics (100Uml 1 penicillin, and 100 mgml 1 streptomycin).
All cultures were maintained at 37 1C in an atmosphere of 5% CO2
in air, pH 7.4.
For in vitro experiments, CRIS (E. chrysanthemi L-Asparagi-
nase, Crisantaspase, EUSA Pharma Ltd., Oxford, UK) was used at
1Uml 1 and MSO at 1mM. The effect of CRIS and MSO was
assessed counting cells with a Coulter Z1 particle counter. Cells
were seeded in complete growth medium in 24-well plates (5 104
cell per well) and grown for 24 h. Growth medium was then
substituted with fresh medium containing the drugs to be tested.
After 72 h, cells were trypsinised and cell number was determined.
Animal experiments. In vivo animal studies were performed
according to the Guidelines for the welfare and use of animals in
cancer research (Workman et al, 2010) and approved by local
ethical Committees, as detailed below.
Assessment of drug toxicity and HepG2 xenografts. To assess
the toxicity of the different drug regimens, 5-week-old male
athymic nude nu/nu mice (Harlan, Udine, Italy) were treated with
intraperitoneal (i.p.) injections of CRIS (5U g 1) and MSO
(10mg kg 1), both in 0.9% NaCl, or vehicle alone; MSO was
injected 3 h after CRIS injection. Treatment was performed three
times a week for 3 weeks. Mice were killed 3 h after the last
injection of MSO, and peripheral blood (PB) and the liver were
immediately collected for analysis. After collection, PB was
centrifuged for serum extraction, and serum was deep frozen
( 80 1C). Serum albumin and Alanine Aminotransferase (Alanine
Transaminase, ALT) were determined with a Dimension Vista
1500 apparatus (Siemens Healthcare Italia, Milan, Italy).
HepG2 xenografts were induced by injecting athymic nude
nu/nu mice (Harlan) subcutaneously (s.c.) with HepG2 cells
(2.5 106 cells). After 8 days, mice were i.p. treated with CRIS and
MSO, alone or in combination as described above. Tumour growth
was monitored for 19 days by external measurement using a
caliper, and tumour volume was calculated by applying the
ellipsoid equation. Three hours after the last MSO injection, which
corresponds to 6 h after CRIS injection, mice were killed, and PB,
tumour masses and livers were collected for analysis. After
collection, PB was centrifuged and the serum was deep frozen.
These experiments were performed at the Laboratory of Genetic
Engineering for the Production of Animal Models (LIGeMa) at the
Animal House of the University of Firenze and were approved by
the Italian Ministry of Health (document no. 140/2009-B).
HC-AFW1 xenografts. Xenografts were induced by injecting
8-week-old NOD.Cg-Prkdcscid IL2rgtmWjl/Sz (NSG) mice (Charles
River, Sulzfeld, Germany) s.c. with 2 106 HC-AFW1 cells. After 2
weeks, mice were treated, as described above, with CRIS, MSO or
CRIS þ MSO. Tumours were inspected every 3 days, and volumes
were calculated by applying the ellipsoid equation. Mice were
weighted every 3 days. After 10 days of treatment, mice were killed
and PB, tumours and livers were explanted for further analysis.
These experiments were performed at the Department of Pediatric
Surgery and Pediatric Urology, University Children’s Hospital,
Tu¨bingen, Germany, and were approved by the local government’s
ethical authority for animal experiments (Regierungspraesidium
Tuebingen, No. K 9/11), which are in line with the guidelines for the
welfare and use of animals in cancer research.
Amino-acid extraction and determination. Amino acids in
serum and tissues and GS activity were measured as previously
described (Tardito et al, 2011; Chiu et al, 2012) with minor
modifications. Samples were de-proteinised with 10% (w/v)
5-sulfosalicylic acid for 30min on ice. Samples were then centrifuged
for 10min at 12000 g at 41C and supernatant was mixed with 1
volume of LiOH buffer (pH 2.2). For tissue amino-acid analysis,
liver and tumour samples were homogenised in 6.6mM solution of
acetic acid in ethanol with a homogeniser (Ingenieurbu¨ro CAT,
M Zipperer, Staufen im Breisgau, Germany) for 30 s on ice.
Samples were then centrifuged 10min at 12000 g at 41C and
supernatants were lyophilised and reconstituted in LiOH buffer
(pH 2.2). The intracellular amino-acid content was determined by
HPLC analysis with a Biochrom 20 amino acid analyser
(Amersham Pharmacia Biotech, Little Chalfont, UK), using a high
resolution column (Bio 20 Peek Lithium) and the physiological
fluid chemical kit (Amersham Pharmacia Biotech) for elution. The
column effluent was mixed with ninhydrin, passed through the
high-temperature reaction coil and read by the photometer unit.
Data were expressed as mmol l 1 serum or nmolmg 1 of tissue.
Glutamine synthetase activity. To assess liver GS activity,
samples were homogenised in a solution containing 50mM
imidazole-HCl, pH 6.8, 0.5mM EDTA, 1mM DTT, supplemented
with protease inhibitors (Complete, Mini, EDTA-free, Roche,
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Basel, Swizterland) for 30 s on ice. Samples were then sonicated on
ice (Sonicator Ultrasonic Processor XL, Misonix, Farmingdale, NY,
USA) and centrifuged for 30min at 12000 g at 41C. After
quantification
(Bio-Rad Protein Assay), protein concentration of the supernatant
was adjusted to 1mgml 1. An aliquot of 150 ml was used for the
assay in a solution of 50mM imidazole-HCl (pH 6.8), 50mM Gln,
25mM hydroxylamine, 25mM sodium arsenate, 2mM MnCl2, and
0.16mM ADP. After incubation at 37 1C for 30min, the reaction
was stopped by the addition of a solution containing 2.42% FeCl3
and 1.45% TCA in 1.82% HCl. Precipitates were removed by
centrifugation (2000 r.p.m. for 5min) and supernatants were read
at 540 nm using a spectrophotometer (Helios-g Spectronic,
Thermo Electron Corporation, Cambridge, UK). Values of GS
activity were expressed as pmol of g-glutamylhydroxamatemin 1
mg 1 protein.
Histopathology and immunostaining. The tumour samples were
fixed in buffered formalin and embedded in paraffin. Section
(4 mm) were stained with H&E for histological analysis. Immuno-
histochemical analyses were performed on all available specimens
using the following primary antibodies: b-Catenin (CTNNB1, BD
Transduction Laboratories, Franklin Lakes, NJ, USA; 1 : 1000), GS
(BD Transduction Laboratories; 1 : 10000), Ki67 (mouse mono-
clonal, Dako Italia S.p.A., Cernusco sul Naviglio, Italy; 1 : 75),
vimentin (clone V9, Roche, 1 : 1000), E-cadherin (clone 36, Roche,
1 : 1000), cytokeratin 7 (CK7, clone SP52, Roche, 1 : 1000),
cytokeratin 19 (CK19, clone A53-B/A2.26, Roche, 1 : 1000),
COX2 (clone SP21 Roche, 1 : 1000). After deparaffinisation and
rehydratation, sections were treated with 3% hydrogen peroxide.
For antigen retrieval, sections were treated with 10mM citrate
buffer at pH 6.0 in a microwave oven. Immunoreactions were
developed with the HRP Polymer (Advance HRP Kit, Dako) and 3-
31Diaminobenzidine. Adequate positive and negative controls were
used in each set of reactions. Reactions were performed on an
automated immunostainer BenchMark XT (Roche).
b-Catenin and Glutamine Synthetase reactivity was scored as
previously described (Dal Bello et al, 2010). For the calculation of
Ki67 index, slides were counterstained in hematoxylin (Mayer’s
Hemalaun, AppliChem GmbH, Darmstadt, Germany) for 10 s and
rinsed in running tap water for 10min. Ki67 index was calculated
counting a minimum of 10 randomly selected high-power ( 400)
fields containing representative sections of tumour and calculated as the
percentage of positively stained cells to total cells (Burcombe et al, 2006).
Gene and protein expression. Gene expression was evaluated
with RT-qPCR using 1mg of total RNA extracted with the
GenElute Mammalian mRNA Miniprep Kit (Sigma Aldrich Srl,
Milan, Italy). PCR reactions were performed in a Rotor-Gene 3000
thermocycler (Corbett Research, Rotor-Gene 3000, version 5.0.60,
Mortlake, Australia) using the GoTaq qPCR Master Mix (Promega
Italia Srl, Milan, Italy) and 5 pmol of each primer. The primers
used were 50-GATTGCCTTCTGTTCAGTGTCT-30 (for) and 50-G
GGTCAACTACCGCCAACC-30 (rev), for Asparagine Synthetase
(ASNS); 50-TCATCTTGCATCGTGTGTGTG-30 (for) and 50-CTT
CAGACCATTCTCCTCCGG-30-(rev) for GS (GLUL); 50-ATGAA
GAAGGCCGAAATGGGA-30 (for) and 50-TGCTTGGTGG
GGTAGGAGTAG-30 (rev) for Solute carrier family 38 member
A2 (SLC38A2); 50-TGGTCTCCTGGATCATGTGG-30 (for) and
50-TTTGCGGGTGAAGAGGAAGT-30 (rev) for Solute carrier
family 1 member A5 (SLC1A5); 50-GCAGCCATCAGGTAAGC
CAAG-30 (for) and 50-AGCGGACCCTCAGAAGAA AGC-30 (rev)
for Ribosomal protein L15 (RPL15).
The reaction consisted of 35 cycles including a denaturation step
at 95 1C for 30 s, followed by separate annealing (30 s, 55 1C–58 1C)
and extension (30 s, 721C) steps. Fluorescence was monitored at
the end of each extension step. A no-template, no-reverse-
transcriptase control was included in each experiment. At the
end of the amplification cycles, a melting curve analysis was added.
Data analysis was performed according to the Relative Standard
Curve Method (Bustin 2000).
For the analysis of protein expression, cells were lysed in RIPA
buffer containing a cocktail of protease inhibitors (Complete, Mini,
EDTA-free, Roche). Lysates were transferred in tubes, sonicated for
5 s, centrifuged at 12 000 g for 10min at 4 1C and aliquots of 35 mg
of proteins were mixed with Laemmli buffer 4 , warmed at 95 1C
for 5min and loaded on a 10% gel for SDS-PAGE. After
electrophoresis, proteins were transferred to PVDF membranes
(Immobilon-P, Millipore Spa, Milan, Italy). Non-specific binding
sites were blocked with an incubation of 2 h at RT in 5% non-fat
dried milk in TBS-Tween solution. The blots were then incubated
at 4 1C overnight with the following antibodies diluted in a 5% BSA
TBS-Tween solution: anti-GS (mouse, monoclonal, 1 : 1500, BD
Transduction Laboratories), anti-b-catenin (mouse, monoclonal,
1 : 1000, Dako), anti p70S6K1 phosphoT389 (rabbit, monoclonal,
1 : 1000, Cell Signaling, Danvers, MA, USA), anti-ASNS (rabbit,
polyclonal, 1 : 1000, Santa-Cruz Biotechnology, Santa Cruz, CA,
USA), anti-vimentin (rabbit, polyclonal, 1 : 1000, Cell Signaling),
anti-E-cadherin (rabbit, polyclonal, 1 : 1000, Cell Signaling), anti-
SLUG (rabbit, polyclonal, 1 : 1000, Cell Signaling), anti-GADPH
(rabbit, polyclonal, 1 : 4000, Sigma Aldrich Srl). After washing,
blots were exposed for 1 h at room temperature to HRP-conjugated
anti mouse or anti-rabbit antibody (Cell Signaling) diluted
1 : 10000 in blocking solution. Immunoreactivity was visualised
with Immobilon Western Chemiluminescent HRP Substrate
(Millipore Spa).
Immunofluorescence. Cells were seeded on 4-chamber Culture
Slides (Falcon, Becton & Dickinson Company, San Jose, CA, USA)
at a density of 4  104 cells cm 2. When 70% of confluence was
reached, cells were rinsed twice in PBS and fixed for 10min in 3.7%
paraformaldehyde in PBS. After two further rinses, cells were
permeabilised for 7min in 0.1% Triton X-100 in PBS. Cells were
then incubated for 1 h in blocking solution (5% of BSA, 10% of
goat serum, and 0.3M glycine in PBS) followed by an overnight
incubation at 4 1C with anti-b-catenin monoclonal antibody
(DakoCytomation Spa, Milan, Italy; M35359, 1 : 200 in PBS 5%
BSA), two washes in PBS, and an additional 1-h incubation with an
Alexa Fluor 488 anti-rabbit IgG antibody (Invitrogen, Paisley, UK,
1 : 400). After one rinse, cells were incubated for 30min with a
100 mgml 1 RNase A solution, and then with a 1mgml 1 solution
of propidium iodide in PBS for 10min to stain nuclei. Cells were
observed with a confocal microscope Zeiss 510 LSM Meta (Carl
Zeiss SpA, Arese, Milan, Italy), using an oil  60 objective. lex of
488 nm and 540 nm and lem of 545 nm and 595 nm were used for
Alexa Fluor 488 and propidium iodide, respectively.
Statistics. Data were expressed as means ±s.d. For statistical
analysis, two-tail Student’s t-test for unpaired samples or one-way
ANOVA were used. GraphPad Prism 5.0 (GraphPad Software Inc.,
La Jolla, CA, USA) was used for all the statistical analyses and
P-values o0.05 were considered statistically significant.
RESULTS
The combined treatment with Asparaginase and MSO depletes
blood glutamine and asparagine. The combined treatment with
5U g 1 CRIS and 10mg kg 1 MSO (three times a week for 3
weeks) was well tolerated by athymic nude mice, with only a
minor, although significant, decrease in body weight and no
significant alterations in liver and spleen weights (Figure 1A).
Treatment caused a marked decrease in the liver content of Gln
and, more evidently, Asn (Figure 1B). In liver homogenates of the
treated animals, MSO was detected (Figure 1B), demonstrating the
tissue uptake of the inhibitor. The hepatic activity of GS
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(Figure 1C), was lowered by497% compared with control. Serum
ALT and albumin, as well as serum urea and creatinine
(Supplementary Table S1), were not significantly different in
control and treated animals (Figure 1D).
Glutaminolytic treatment suppresses the growth of HCC cell
xenografts. The growth of HepG2 xenografts was significantly
reduced after 19 days of treatments. Tumour size was reduced by
51% and 60% by single treatment with CRIS or MSO, respectively
(Figure 2A), whereas it was completely suppressed by the
combined treatment. At histopathological analysis no viable
tumour cells were detectable in this group of animals and,
instead, fibrous tissue with a lympho-macrophagic infiltrate was
observed at the injection site consistent with complete tumour
regression (Figure 3B, lower left). The tumour weight of treated
animals was also reduced by 34% with CRIS and 61% with MSO
(Figure 2B and C).
The HepG2 xenografts (Figure 3A) showed a diffuse nuclear
expression of b-catenin and a corresponding loss of membrane
expression of E-cadherin. The pattern and the intensity of
immunoreactivity were not modified by the different treatment
regimens (not shown). HepG2 tumours were also intensely positive
for GS (Figure 3B, top left), and the expression of the enzyme was
not appreciably increased by either CRIS (Figure 3B, top right) or
MSO (Figure 3B, bottom right). Glutamine synthetase-positive
cells were not detected in the tissue surrounding the injection site
of animals treated with CRIS and MSO, confirming that the grafted
cells were completely cleared by the treatment (Figure 3B, bottom
left). The liver tissue of control mice showed expression of GS in a
single row of hepatocytes around the central hepatic venule.
The number of perivenular hepatocytes stained with GS was
increased in the animals receiving the combination of CRIS þ
MSO (Figure 3C). To assess the potential emergence of resistant
tumour clones with features of progenitor liver cells and/or
epithelial-mesenchymal transition, we performed on all available
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tumour samples immunostaining for markers of hepatocellular
stemness (vimentin, CK7, CK19, (van Zijl et al, 2009) or enzymes
known to be modulated by glutamine depletion in other tumour
models (COX2, (Singh et al, 2012)). A variable expression of all
these markers was observed irrespective of tumour size or
treatment schedule (data not shown).
Serum amino acids in the four experimental conditions are
shown in Figure 3D. Crisantaspase, alone or in combination with
MSO, caused a substantial depletion of serum Asn and Gln. MSO
alone did not affect serum Asn or Gln, but produced a significant
decrease in serum Glu compared with untreated controls. More-
over, CRIS significantly decrease the content of Asn, Glu and Gln
in the tumour tissue (Figure 3E).
The combined treatment hinders the growth of xenografts of
CTNNB1-mutated, asparaginase-resistant HC-AFW1 cells. To
ascertain if the behaviour exhibited by HepG2 cells was shared
by other CTNNB1-mutated HCC cell lines, we investigated
the sensitivity to Gln depletion of HC-AFW1 cells. These cells
harbour a CTNNB1 deletion in exon 3, distinct from that present in
HepG2 cells (Armeanu-Ebinger et al, 2012); however, in both
cell lines the mutations result in the nuclear accumulation of
b-catenin (Figure 4A). Although the growth of HepG2 cells
was markedly hindered by CRIS (Tardito et al, 2011), HC-AFW1
cells were substantially unaffected (Figure 4B) and both lines were
insensitive to MSO alone. On the contrary, in the presence of CRIS,
MSO dramatically reduced the growth of both cell lines.
To gain further insight on the differential effect of treatment on
HepG2 and HC-AFW1 cells, the expression of genes involved in
Gln metabolism and transport was investigated (Figure 4C). The
GLUL gene, coding for GS, was more expressed in HC-AFW1 than
in HepG2 cells, whereas ASNS, SLC38A2 (SNAT2 transporter) and
SLC1A5 (ASCT2 transporter) were more expressed in HepG2 cells.
The higher expression of GS in HC-AFW1 cells was also confirmed
by western blot analysis (Figure 4D).
Glutamine synthetase expression was increased by treatment with
CRIS or CRIS þ MSO, and this effect was more evident in HepG2
than in HC-AFW1 cells. This is likely correlated with the depletion of
intracellular Gln that leads to GS stabilisation (Tardito et al, 2011).
Indeed, a 24-h treatment with CRIS lowered cell Gln from
75nmolesmg 1 of protein, under control conditions, to undetect-
able levels (o1nmolemg 1 of protein) in HepG2 cells, and from
51nmolesmg 1 of protein to 16nmolesmg 1 of protein in HC-
AFW1 cells. The different degree of intracellular Gln depletion was
also reflected by the different behaviour of the phosphorylated form
of p70S6K1, a bona fide readout for mTOR activity, which was
decreased by CRIS in HepG2 but not in HC-AFW1 cells (Figure 4D).
Interestingly, as already described by our group (Tardito et al, 2012),
in CRIS-treated cells, MSO causes a paradoxical activation of mTOR
that is more evident in HepG2 than in HC-AFW1 cells.
When treatments were performed on HC-AFW1 xenografts
(Panels E–H), only the combined treatment with CRIS þ MSO
produced a significant decrease (60%) in the mean weight of
tumours at the time of killing (Figure 4E and F). Crisantaspase or,
at a lesser degree, MSO alone also decreased tumour weight,
without reaching statistical significance. However, when the
tumour volumes were matched to their respective initial value,
all treatments caused a significant delay in tumour growth
(Figure 4G). The Ki67 index, an indicator of proliferative activity
of the tumour, was significantly lowered by CRIS or CRIS þ MSO,
but not by MSO alone (Figure 4H). The expression of markers of
epithelial-mesenchymal transition (vimentin, E-cadherin and
SLUG) was not consistently changed by treatments also in HC-
AFW1 tumours (Supplementary Figure S1).
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DISCUSSION
In this report, we show that two CTNNB1-mutated HCC models
are sensitive to Gln depletion, obtained in vivo with the
administration of CRIS, a drug in clinical use for Acute
Lymphoblastic Leukaemia, and of the irreversible GS inhibitor
MSO. The effect of CRIS treatment was differentially evident in the
two cell lines, which harbour distinct CTNNB1 mutations, the
HepG2 cells being more sensitive than the HC-AFW1 cells both
in vitro and in vivo.
The combined treatment with CRIS and MSO exhibits only a
mild toxicity in vivo as shown by a minor decrease in body weight
in nude mice (Figure 1), confirmed in NSG mice (results not
shown). Indices of liver, kidney and muscle function, such as
serum albumin, ALT, urea and creatinine levels, are not
significantly altered. However, given the possibility that glutamine
depletion and inhibition of GS activity have detrimental effects on
central nervous and immune systems, the toxicity of the treatment
deserves further investigation in different models.
The hypothesised biochemical mechanisms for the antitumour
effect of the treatment are shown in Figure 5. Besides asparagine
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hydrolysis, it is known that CRIS hydrolyses extracellular Gln
((Avramis 2012; Covini et al, 2012) and Figure 3D), and MSO
inhibits GS activity, thus preventing intracellular synthesis of Gln.
As a result, the cell content of Gln decreases at levels not
permissive for cell proliferation, and HCC growth is hampered.
In animals with HepG2 xenografts treated with CRIS alone,
tumour Gln is decreased by 50%. It is likely that this partial effect is
due to the rescue of plasma Gln after the initial depletion that
follows CRIS administration. Indeed, in leukaemia patients treated
with bacterial asparaginases, only transient Gln depletion can be
observed (Ollenschlager et al, 1988). Nonetheless, a significant
delay in HepG2 and HC-AFW1 xenograft growth is observed in
animals treated with CRIS alone, suggesting that even a partial Gln
depletion has severe metabolic consequences for CTNNB1-mutated
HCC cells.
Cancer cells acquire metabolic properties significantly different
from those of normal cells, such as dysregulated glucose
metabolism, stimulated fatty acid synthesis and enhanced gluta-
minolysis (DeBerardinis et al, 2007; Zhao et al, 2013). In many
cancer models, these alterations are driven by oncogene activation
or inactivating mutations of oncosuppressors. The b-catenin/Wnt
pathway is activated in a significant proportion of HCC, but it has
not been so far associated with major differences in the central
carbon metabolism (Beyoglu et al, 2013), although the activation of
this pathway is associated with distinctive transcriptional, patho-
logical and clinical features (Boyault et al, 2007); yet, CTNNB1
mutations are strongly associated with the induction of genes
involved in Gln metabolism (Cadoret et al, 2002), suggesting that
the mutated CTNNB1 rewires cell metabolism towards a more Gln-
dependent phenotype. Previous work from our (Tardito et al,
2011) as well as from other groups (Cheng et al, 2011) indicated
that CTNBB1-mutated HepG2 cells are very sensitive to Gln
starvation in vitro. The present report demonstrates that this
sensitivity is also maintained in vivo. On the basis of these data, we
have hypothesised that CTNNB1 mutations promote Gln addiction
in HCC.
Another CTNNB1-mutated model, the HC-AFW1 cells
(Figure 4A–D), differently from HepG2 cells, are resistant to CRIS
in vitro and, consistently, maintain appreciable intracellular levels
of Gln even when the extracellular amino acid is completely
depleted. This behaviour is likely due to the higher expression of
GS in HC-AFW1 cells. The divergent sensitivity to CRIS of HepG2
and HC-AFW1 cells suggests that different CTNNB1 mutations
may have distinct effects on Gln metabolism in tumour cells. The
low expression of transport systems for Gln, like SNAT2 and
ASCT2 (Figure 4C), may also contribute to shield the intracellular
compartment from Gln depletion, slowing the efflux of the amino
acid from HC-AFW1 cells. The residual Gln content, maintained
in this cell model, preserves the activity of mTOR, which is instead
progressively lowered in CRIS-treated HepG2 cells (Figure 4D).
HC-AFW1 cells, when xenografted in mice, are sensitive to the
combined treatment with CRIS and MSO. Interestingly, when
tumour volumes before killing (Figure 4G) were matched and
normalised to the initial tumour volume size at the beginning of
the treatments, CRIS and MSO, even when used alone, showed
significant effects on tumour growth. Thus HC-AFW1 cells seem
more sensitive to Gln depletion in vivo than in vitro. This paradox
may be explained considering that the extracellular concentration
of Gln is markedly higher in the culture medium (2mM) than in
serum (0.6mM). Moreover, the HC-AFW1 cell line was derived
from a paediatric HCC, a tumour that has distinctive epidemiol-
ogy, aetiology, clinical behaviour and response to therapy
compared with adult HCC (Emre and McKenna, 2004). Therefore,
biological differences with the HepG2 cell line are to be expected
despite the sharing of CTNNB1 mutations.
The possibility to hinder HCC growth through a metabolic
approach based on amino-acid depletion has been recently
investigated (Zhang et al, 2013), and it has been demonstrated
that the knockdown of ASNS markedly increased the sensitivity to
CRIS, both in vitro and in vivo. In our case, CRIS-resistant HC-
AFW1 cells express much less ASNS than CRIS-sensitive HepG2
cells, indicating that CRIS resistance is not always linked to high
ASNS expression and that additional factors determine
CRIS antitumour effect. However, it should be noted that CRIS
resistance, as evaluated in leukaemia cells, is a complex
phenomenon (Aslanian and Kilberg, 2001), possibly attributable
to the contribution of different mechanisms.
In summary, the results presented in this report indicate that the
growth of human CTNNB1-mutated HCC xenografts is delayed by
Gln restriction. Even the sole, likely transient depletion of
circulating Gln, achieved by CRIS administration, is able to hinder
tumour growth. Increasing evidence indicates that targeting
tumour metabolism constitutes a promising strategy and may
widen the therapeutic window of traditional chemotherapeutic
agents (Zhao et al, 2013). Compared with pharmacological
inhibitors of b-catenin or anti-b-catenin siRNA, which have been
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tested on HCC cells (Behari et al, 2007; Zeng et al, 2007),
glutamine-depleting drugs act downstream of b-catenin on one of
its targets, thus possibly causing fewer side effects on normal
tissues that need b-catenin activation (Nejak-Bowen and Monga,
2011).
Further experiments will be needed to elucidate the relation-
ships between b-catenin pathway and Gln addiction in HCC and,
in particular, if the approach described in this contribution is also
effective in HCC with wild type CTNNB1. However, the data
presented suggest that Gln depletion may constitute a pharmaco-
logically achievable, metabolic approach to control CTNNB1-
mutated HCC.
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